Evidence map›Paper›PMID 33559191›Full record

ArticlePhotochemistry and photobiology2022

Fine-Feature Modifications to Strained Ruthenium Complexes Radically Alter Their Hypoxic Anticancer Activity

Houston D Cole, John A Roque, Liubov M Lifshits, Rachel Hodges, Patrick C Barrett, Dmytro Havrylyuk, David Heidary, Elamparuthi Ramasamy, Colin G Cameron, Edith C Glazer and 1 more

Abstract read
In one paragraph

Article in Photochemistry and photobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Ruthenium-Based Photoactivated Chemotherapy.Journal of the American Chemical Society · 2023
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Houston D ColeDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, USA.
John A RoqueDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, USA.
Liubov M LifshitsDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, USA.
Rachel HodgesDepartment of Chemistry and Biochemistry, The University of North Carolina at Greensboro, Greensboro, NC, USA.
Patrick C BarrettDepartment of Chemistry and Biochemistry, The University of North Carolina at Greensboro, Greensboro, NC, USA.
Dmytro HavrylyukDepartment of Chemistry, University of Kentucky, Lexington, KY, USA.
David HeidaryDepartment of Chemistry, University of Kentucky, Lexington, KY, USA.
Elamparuthi RamasamyDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, USA.
Colin G CameronDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, USA.ORCID 0000-0003-0978-0894
Edith C GlazerDepartment of Chemistry, University of Kentucky, Lexington, KY, USA.ORCID 0000-0002-0190-7742
Sherri A McFarlandDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX, USA.ORCID 0000-0002-8028-5055

Funding

Immunomodulating Ruthenium Metal Complexes for Melanoma PhotodynamicTherapyR01CA222227 · NCI · UNIVERSITY OF TEXAS ARLINGTON · PI GUJAR, SHASHI, MCFARLAND, SHERRI · 2018 to 2022
$2.6M
Role of small molecule interactions and multiprotein assemblies in CYP1B1 disease-associated function and dysfunctionR01GM138882 · NIGMS · UNIVERSITY OF KENTUCKY · PI GLAZER, EDITH C, HEIDARY, DAVID · 2020 to 2024
$1.9M
Light-responsive ruthenium compounds for applications in diseaseR01GM107586 · NIGMS · UNIVERSITY OF KENTUCKY · PI GLAZER, EDITH C · 2014 to 2019
$1.7M
NCI NIH HHS R01 CA222227NIGMS NIH HHS R01 GM107586NIGMS NIH HHS R01 GM138882
6 · The paper itself

Abstract

In an earlier study of π-expansive ruthenium complexes for photodynamic and photochemo-therapies, it was shown that a pair of structural isomers differing only in the connection point of a naphthalene residue exhibited vastly different biological activity. These isomers are further explored in this paper through the activity of their functionalized derivatives. In normoxia, the inactive 2-NIP isomer (5) can be made as photocytotoxic as the active 1-NIP isomer (1) by functionalizing with methyl or methoxy groups, while methoxy variants of the 1-NIP isomer became inactive. In all cases, the singlet oxygen sensitization quantum yield was below 1%. Hypoxic photocytotoxicity was attenuated, with only three of the series showing any activity, notwithstanding the photodissociative ligands. The results here are consistent with the earlier findings in that seemingly minor structural modifications on the non-strained ligand can dramatically modulate the normoxic and hypoxic activity of these strained compounds and that these changes appear to exert a greater influence on photocytotoxicity than singlet oxygen sensitization or rates of photosubstitution in cell-free conditions would suggest.

Indexed as

Antineoplastic AgentsCoordination ComplexesRutheniumLigandsSinglet OxygenAntineoplastic AgentsCoordination ComplexesLigandsRutheniumSinglet Oxygen

Identifiers

PMID33559191
PMCPMC8349932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.